NUVAIRA
Manufacturing · Minnesota, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
6500 Wedgwood Rd N Ste 100, Minneapolis,...Phone Number
(763) 450-2800Website
www.nuvaira.comRevenue
$16.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About NUVAIRA
Nuvaira specializes in innovative therapies for Chronic Obstructive Pulmonary Disease (COPD), focusing on a catheter-based system designed to treat overactive airways. Their flagship product, the dNerva Lung Denervation System, offers a one-time outpatient procedure that aims to improve lung function and reduce symptoms for patients with lung hyperinflation and low emphysema. The company targets individuals suffering from COPD who may not find relief from traditional inhaled therapies. Nuvaira's approach is supported by clinical evidence demonstrating lasting improvements in symptoms and overall COPD outcomes.Explore more
NUVAIRA Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NUVAIRA your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if NUVAIRA has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once NUVAIRA has new funding data
Earning: See what the market has to say on NUVAIRA recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at NUVAIRA
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when NUVAIRA launches new products
Click to see if NUVAIRA had a recent Job posting/layoffs
NUVAIRA, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if NUVAIRA is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to NUVAIRA
Compare insights from companies similar to NUVAIRA, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NUVAIRA is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NUVAIRA is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NUVAIRA.
NUVAIRA financials insights
Gather financial insights about NUVAIRA, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series A
$3M
2012
Private Equity
$10.6M
Series B
$11M
2013
Series C
$10M
2014
Series D
$42M
2019
Private Equity
$79M
2026
Private Equity
$35.8M
NUVAIRA Tech Stack
A closer look at the technologies used by NUVAIRA
Most Recent Scoops
Person-Based
Funding, Finance
Funding
Funding
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
NUVAIRA News & Media
Nuvaira Announces AIRFLOW-3 COPD Pivotal Trial Milestone
100 Randomized Patients; Inspire's CEO Tim Herbert appointed Chairman of the Board MINNEAPOLIS, Aug. 11, 2021 /PRNewswire/ -- Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that 100 patients have been randomized in the FDA pivotal...Nuvaira Announces Published Two-Year Results in COPD Patients treated with Targeted Lung Denervation
MINNEAPOLIS, Nov. 23, 2020 /PRNewswire/ -- Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, announced today publication of two-year follow-up data from its randomized, sham-controlled, double-blinded trial (AIRFLOW-2) that confirms long-term safety...Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device
MINNEAPOLIS, June 8, 2020 /PRNewswire/ -- Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that its Nuvaira® Lung Denervation System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA). This...Nuvaira Announces Peer-Reviewed Publications of Targeted Lung Denervation Mechanisms of Action and Clinical Outcomes
AIRFLOW-2 randomized, sham-controlled one-year data accepted by AJRCCM MINNEAPOLIS, Aug. 19, 2019 /PRNewswire/ -- Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, announced today multiple peer-reviewed publications that provide further evidence of...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NUVAIRA
Sign Up For FreeTo access detailed company insights
Nuvaira specializes in innovative therapies for Chronic Obstructive Pulmonary Disease (COPD), focusing on a catheter-based system designed to treat overactive airways. Their flagship product, the dNerva Lung Denervation System, offers a one-time outpatient procedure that aims to improve lung function and reduce symptoms for patients with lung hyper... Read More
